| Identification | More | [Name]
Carbazochrome sodium sulfonate | [CAS]
51460-26-5 | [Synonyms]
1-METHYL-6-OXO-2,3,5,6-TETRAHYDROINDOLE-5-SEMICARBAZONO-2-SULFONIC ACID SODIUM SALT 3 HYDRATE
CARBAZOCHROME SODIUM SULFONATE
CARBAZOCHROME SODIUM SULFONATE TRIHYDRATE
1h-indole-2-sulfonicacid,5-((aminocarbonyl)hydrazono)-2,3,5,6-tetrahydro-1-me
ac-17trihydrate
adonatrihydrate
adrenochromesulfonateac17trihydrate
sodium1-methyl-5-semicarbazono-6-oxo-2,3,5,6-tetrahydroindole-3-sulfonate
thyl-6-oxo-,monosodiumsalt,trihydrate
CarbazochromeSodiumSulfonateC10H11N4Nao5S3H2O
CARBAZOCHROMESODIUMSULPHONATE
1H-Indole-2-sulfonic acid, 5-[(aminocarbonyl)hydrazono]-2,3,5,6-tetrahydro-1-methyl-6-oxo-, monosodium salt
2-Indolinesulfonic acid, 5,6-dihydro-1-methyl-5,6-dioxo-, 5-semicarbazone, sodium salt (7CI)
Adenaron
Adona
Adrenochrome sulfonate Ac 17
Carbazon
Donaseven
Emex
Odanon | [EINECS(EC#)]
257-217-0 | [Molecular Formula]
C10H17N4NaO8S | [MDL Number]
MFCD00211294 | [Molecular Weight]
376.32 | [MOL File]
51460-26-5.mol |
| Chemical Properties | Back Directory | [Melting point ]
approximate 210℃(dec.) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO (Sparingly), Methanol (Slightly) | [form ]
Solid | [color ]
Yellow to Dark Orange | [PH]
pH (16g/l, 25℃) 5.0～6.0 | [Stability:]
Hygroscopic, Moisture Sensitive, Temperature Sensitive | [InChIKey]
HLFCZZKCHVSOAP-DAMYXMBDSA-M | [CAS DataBase Reference]
51460-26-5(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
Carbazochrome sodium sulfonate is Yellow Solid
| [Uses]
Carbazochrome is an antihemorrhagic for use in the treatment of hemorrhoids. | [Uses]
Carbazochrome sodium sulfonate is a Phosphatidylinositol hydrolysis inhibitor in endothelial cells.
| [in vivo]
Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of radiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats[2]. | Animal Model: | Male Sprague-Dawley rats weighing 180-230 g[2] | | Dosage: | 1, 5 and 10 mg/kg | | Administration: | I.v.; injected 30, 60, or 90 min before Ioxaglate injection (4 g I/kg, i.v.). | | Result: | Attenuated the Ioxaglate-increased vascular permeability at the dose of 1, 5 and 10 mg/kg in a dose-dependent manner, achieving statistical significance at 5 and 10 mg/kg. |
|
|
|